Eli Lilly signs a landmark $2.75 billion deal with AI drug pioneer Insilico Medicine, offering $115 million upfront to fast-track AI-generated drugs across multiple disease areas into global markets.
NVIDIA CEO Jensen Huang declares AI infrastructure the largest buildout in human history, requiring trillions in investment across a five-layer stack of energy, chips, infrastructure, models, and applications, as open source models accelerate adoption and industries from drug discovery to robotics begin generating measurable economic value.
MIT and Microsoft researchers are using AI to design nanoparticle sensors that detect early-stage cancer through a simple urine test, with scientists now working to develop an at-home diagnostic kit capable of identifying up to 30 types of cancer.
AI adoption in healthcare is surging, with 70% of organizations now using the technology in 2026, delivering powerful financial returns as 85% of executives report increased revenue and 80% cite reduced costs, fueling massive budget increases across the industry.
Isomorphic Labs unleashes IsoDDE, a groundbreaking AI drug-discovery engine that outperforms open-source rivals in predicting drug-protein interactions, but scientists are raising concerns as the powerful DeepMind spin-off keeps its technology fully proprietary, blocking the broader research community from replicating or building on its breakthroughs.
A former Anthropic Claude product leader joins Google as VP of Product for Vertex AI and Agents, bringing insider AI expertise to accelerate enterprise adoption while warning that trust barriers around accountability are slowing deployment, and advising companies to start with narrow, low-risk workflows before scaling up.
AI stocks crash despite companies like Amazon, Alphabet, and chip manufacturers posting record double-digit growth and Amazon announcing $200 billion infrastructure investment, prompting analysts to declare the selloff a rare once-in-a-decade buying opportunity as the transformative technology remains in early development stages.
NVIDIA launches a $1 billion AI drug discovery lab with pharmaceutical giant Lilly and expands its BioNeMo platform, partnering with major life sciences companies to automate scientific discovery through AI models that predict molecular structures and connect digital agents to robotic laboratory systems.
NVIDIA and Eli Lilly unveil a groundbreaking $1 billion AI co-innovation lab that promises to revolutionize drug discovery by creating a continuous learning system connecting physical laboratories with computational AI for round-the-clock experimentation and pharmaceutical development.
Excelsior Sciences secures $95 million to revolutionize drug discovery by replacing human chemists with AI-powered robots that break down FDA-approved molecules into 'smart bloccs' and reassemble them into new pharmaceutical compounds, promising faster and cheaper development while reshoring manufacturing to the US.